Handelen Schrödinger, Inc. - SDGR CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.12 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024874% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.002651% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 24.46 |
Open* | 24.96 |
1-Jaarlijkse Verandering* | -30.57% |
Dagelijks bereik* | 24.4 - 25.16 |
52 wekelijks bereik | 15.85-36.33 |
Weekgemiddelde volume (10 dagen) | 483.19K |
Gemiddeld volume (3 maanden) | 12.02M |
Marktkapitalisatie | 1.74B |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 71.49M |
Omzet | 180.96M |
EPS | -2.10 |
Dividend (opbrengst %) | N/A |
Beta | -100.00K |
Volgende inkomsten datum | May 2, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Mar 29, 2023 | 24.46 | 0.21 | 0.87% | 24.25 | 25.02 | 24.25 |
Mar 28, 2023 | 24.08 | -1.11 | -4.41% | 25.19 | 25.51 | 24.08 |
Mar 27, 2023 | 25.58 | 0.08 | 0.31% | 25.50 | 25.91 | 24.97 |
Mar 24, 2023 | 25.48 | 0.52 | 2.08% | 24.96 | 25.75 | 24.91 |
Mar 23, 2023 | 25.46 | -0.56 | -2.15% | 26.02 | 26.82 | 24.78 |
Mar 22, 2023 | 25.85 | -0.49 | -1.86% | 26.34 | 27.24 | 25.18 |
Mar 21, 2023 | 26.70 | 1.38 | 5.45% | 25.32 | 27.02 | 25.14 |
Mar 20, 2023 | 25.23 | 0.18 | 0.72% | 25.05 | 25.69 | 24.47 |
Mar 17, 2023 | 25.43 | -0.24 | -0.93% | 25.67 | 26.54 | 24.89 |
Mar 16, 2023 | 26.51 | 1.35 | 5.37% | 25.16 | 26.72 | 25.07 |
Mar 15, 2023 | 25.55 | 1.08 | 4.41% | 24.47 | 25.74 | 24.29 |
Mar 14, 2023 | 25.48 | 0.76 | 3.07% | 24.72 | 25.64 | 24.43 |
Mar 13, 2023 | 24.30 | 1.39 | 6.07% | 22.91 | 24.39 | 22.19 |
Mar 10, 2023 | 23.32 | -1.20 | -4.89% | 24.52 | 24.74 | 22.54 |
Mar 9, 2023 | 24.78 | -0.40 | -1.59% | 25.18 | 25.68 | 24.50 |
Mar 8, 2023 | 25.30 | 0.24 | 0.96% | 25.06 | 25.65 | 24.70 |
Mar 7, 2023 | 25.14 | 0.23 | 0.92% | 24.91 | 25.88 | 24.33 |
Mar 6, 2023 | 24.98 | -1.31 | -4.98% | 26.29 | 26.29 | 24.87 |
Mar 3, 2023 | 26.03 | 1.78 | 7.34% | 24.25 | 26.22 | 23.31 |
Mar 2, 2023 | 24.27 | 0.31 | 1.29% | 23.96 | 25.64 | 23.74 |
Schrödinger, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 180.955 | 137.931 | 108.095 | 85.543 | 66.639 |
Inkomsten | 180.955 | 137.931 | 108.095 | 85.543 | 66.639 |
Kosten van opbrengsten, totaal | 79.933 | 72.311 | 44.623 | 36.45 | 23.702 |
Brutowinst | 101.022 | 65.62 | 63.472 | 49.093 | 42.937 |
Totale bedrijfskosten | 327.772 | 249.374 | 169.011 | 124.258 | 94.608 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 121.467 | 86.159 | 59.693 | 46.291 | 34.259 |
Onderzoek & Ontwikkeling | 126.372 | 90.904 | 64.695 | 38.786 | 34.215 |
Bedrijfsresultaat | -146.817 | -111.443 | -60.916 | -38.715 | -27.969 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -2.309 | 10.635 | 34.624 | 12.743 | -0.379 |
Netto inkomen voor belastingen | -149.126 | -100.808 | -26.292 | -25.972 | -28.348 |
Netto inkomen na belastingen | -149.189 | -101.219 | -26.637 | -25.681 | -28.425 |
Netto inkomen voor extra. Posten | -149.186 | -100.393 | -24.463 | -24.571 | -28.425 |
Totale buitengewone posten | |||||
Netto inkomen | -149.186 | -100.393 | -24.463 | -24.571 | -28.425 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -149.186 | -100.393 | -24.463 | -24.571 | -28.425 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -149.186 | -100.393 | -24.463 | -24.571 | -28.425 |
Verwaterd Netto Inkomen | -149.186 | -100.393 | -24.463 | -24.571 | -28.425 |
Verwaterd Gewogen Gemiddelde Aandelen | 71.1734 | 70.5949 | 60.0247 | 61.4472 | 61.4472 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.09609 | -1.4221 | -0.40755 | -0.39987 | -0.46259 |
Dividends per Share - Common Stock Primary Issue | 0 | ||||
Verwaterde Genormaliseerde Winst per Aandeel | -2.09609 | -1.4221 | -0.40755 | -0.39987 | -0.46259 |
Depreciation / Amortization | 2.731 | 2.432 | |||
Minderheidsbelang | 0.003 | 0.826 | 2.174 | 1.11 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Totale inkomsten | 56.843 | 36.98 | 38.469 | 48.663 | 46.17 |
Inkomsten | 56.843 | 36.98 | 38.469 | 48.663 | 46.17 |
Kosten van opbrengsten, totaal | 18.139 | 19.779 | 21.335 | 20.68 | 19.809 |
Brutowinst | 38.704 | 17.201 | 17.134 | 27.983 | 26.361 |
Totale bedrijfskosten | 85.381 | 83.143 | 81.942 | 77.306 | 68.685 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 32.7 | 30.479 | 29.484 | 28.804 | 23.731 |
Onderzoek & Ontwikkeling | 34.542 | 32.885 | 31.123 | 27.822 | 25.145 |
Bedrijfsresultaat | -28.538 | -46.163 | -43.473 | -28.643 | -22.515 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 1.194 | 6.501 | -4.168 | -5.836 | -7.926 |
Netto inkomen voor belastingen | -27.344 | -39.662 | -47.641 | -34.479 | -30.441 |
Netto inkomen na belastingen | -27.208 | -39.856 | -47.674 | -34.451 | -30.715 |
Minderheidsbelang | 0.001 | 0.003 | -0.012 | 0.011 | 0.002 |
Netto inkomen voor extra. Posten | -27.207 | -39.853 | -47.686 | -34.44 | -30.713 |
Netto inkomen | -27.207 | -39.853 | -47.686 | -34.44 | -30.713 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -27.207 | -39.853 | -47.686 | -34.44 | -30.713 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -27.207 | -39.853 | -47.686 | -34.44 | -30.713 |
Verwaterd Netto Inkomen | -27.207 | -39.853 | -47.686 | -34.44 | -30.713 |
Verwaterd Gewogen Gemiddelde Aandelen | 71.2716 | 71.208 | 71.1619 | 71.0504 | 70.9341 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.38174 | -0.55967 | -0.67011 | -0.48473 | -0.43298 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Verwaterde Genormaliseerde Winst per Aandeel | -0.38174 | -0.55967 | -0.67011 | -0.48473 | -0.43298 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totaal vlottende activa | 625.06 | 682.978 | 118.536 | 104.69 | 48.054 |
Geldmiddelen en kortetermijnbeleggingen | 576.479 | 642.691 | 85.83 | 84.067 | 36.343 |
Geldmiddelen & Equivalenten | 120.267 | 202.296 | 25.986 | 77.716 | 9.96 |
Korte Termijn Investeringen | 456.212 | 440.395 | 59.844 | 6.351 | 26.383 |
Totale Vorderingen, Netto | 40.551 | 35.378 | 25.738 | 18.021 | 9.759 |
Accounts Receivable - Trade, Net | 40.015 | 35.012 | 25.58 | 17.995 | 9.759 |
Prepaid Expenses | 5.03 | 4.409 | 6.468 | 2.602 | 1.952 |
Total Assets | 756.487 | 746.263 | 155.27 | 120.73 | 58.022 |
Property/Plant/Equipment, Total - Net | 85.409 | 15.269 | 19.03 | 7.967 | 5.439 |
Property/Plant/Equipment, Total - Gross | 97.764 | 29.071 | 29.592 | 17.4 | 14.677 |
Accumulated Depreciation, Total | -12.355 | -13.802 | -10.562 | -9.433 | -9.238 |
Intangibles, Net | 0 | 0.015 | 0.052 | ||
Long Term Investments | 43.167 | 45.664 | 15.366 | 5.444 | 2.609 |
Other Long Term Assets, Total | 2.851 | 2.352 | 2.338 | 2.614 | 1.868 |
Total Current Liabilities | 91.211 | 73.205 | 45.02 | 27.005 | 17.818 |
Accounts Payable | 8.079 | 8.398 | 3.524 | 2.773 | 1.61 |
Accrued Expenses | 27.764 | 19.404 | 16.442 | 6.587 | 5.052 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 55.368 | 45.403 | 25.054 | 17.645 | 11.156 |
Total Liabilities | 199.416 | 122.248 | 57.054 | 30.603 | 21.074 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 108.191 | 49.039 | 11.993 | 3.598 | 3.256 |
Total Equity | 557.071 | 624.015 | 98.216 | 90.127 | 36.948 |
Preferred Stock - Non Redeemable, Net | 0 | 191.58 | 161.687 | 82.31 | |
Common Stock | 0.71 | 0.699 | 0.061 | 0.059 | 0.055 |
Additional Paid-In Capital | 786.964 | 752.558 | 11.655 | 8.915 | 6.71 |
Retained Earnings (Accumulated Deficit) | -229.952 | -129.559 | -105.096 | -80.525 | -52.1 |
Other Equity, Total | -0.651 | 0.317 | 0.016 | -0.009 | -0.027 |
Total Liabilities & Shareholders’ Equity | 756.487 | 746.263 | 155.27 | 120.73 | 58.022 |
Total Common Shares Outstanding | 70.9987 | 69.8777 | 61.4472 | 61.4472 | 61.4472 |
Other Current Assets, Total | 3 | 0.5 | 0.5 | ||
Minority Interest | 0.014 | 0.004 | 0.041 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totaal vlottende activa | 586.168 | 625.06 | 622.025 | 649.788 | 675.238 |
Geldmiddelen en kortetermijnbeleggingen | 525.532 | 576.479 | 597.186 | 613.591 | 648.494 |
Geldmiddelen & Equivalenten | 117.257 | 120.267 | 160.879 | 117.699 | 133.122 |
Korte Termijn Investeringen | 408.275 | 456.212 | 436.307 | 495.892 | 515.372 |
Totale Vorderingen, Netto | 45.594 | 40.551 | 16.33 | 25.904 | 18.29 |
Accounts Receivable - Trade, Net | 44.086 | 40.015 | 16.347 | 25.953 | 17.974 |
Prepaid Expenses | 11.542 | 5.03 | 5.509 | 7.293 | 7.954 |
Other Current Assets, Total | 3.5 | 3 | 3 | 3 | 0.5 |
Total Assets | 719.537 | 756.487 | 762.617 | 717.334 | 744.189 |
Property/Plant/Equipment, Total - Net | 89.256 | 85.409 | 85.533 | 14.451 | 13.664 |
Long Term Investments | 37.002 | 43.167 | 51.087 | 49.713 | 52.931 |
Other Long Term Assets, Total | 1.334 | 2.851 | 3.972 | 3.382 | 2.356 |
Total Current Liabilities | 85.532 | 91.211 | 72.916 | 70.378 | 67.621 |
Accounts Payable | 9.766 | 8.079 | 8.228 | 5.96 | 7.22 |
Accrued Expenses | 21.995 | 27.764 | 20.814 | 20.349 | 19.642 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 53.771 | 55.368 | 43.874 | 44.069 | 40.759 |
Total Liabilities | 188.87 | 199.416 | 182.811 | 111.583 | 112.421 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0.003 | 0.014 | 0.016 | 0.02 | 0.008 |
Other Liabilities, Total | 103.335 | 108.191 | 109.879 | 41.185 | 44.792 |
Total Equity | 530.667 | 557.071 | 579.806 | 605.751 | 631.768 |
Common Stock | 0.712 | 0.71 | 0.709 | 0.708 | 0.705 |
Additional Paid-In Capital | 797.004 | 786.964 | 778.292 | 769.199 | 760.574 |
Retained Earnings (Accumulated Deficit) | -264.392 | -229.952 | -199.239 | -164.232 | -129.588 |
Other Equity, Total | -2.657 | -0.651 | 0.044 | 0.076 | 0.077 |
Total Liabilities & Shareholders’ Equity | 719.537 | 756.487 | 762.617 | 717.334 | 744.189 |
Total Common Shares Outstanding | 71.1366 | 70.9987 | 70.8676 | 70.7178 | 70.4649 |
Goodwill, Net | 4.791 | ||||
Intangibles, Net | 0.986 |
- Jaarlijks
- Per kwartaal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -101.219 | -26.637 | -25.681 | -28.425 | -17.392 |
Geldmiddelen uit Operationele Activiteiten | -70.669 | 16.757 | -26.059 | -23.711 | -15.307 |
Geldmiddelen uit Operationele Activiteiten | 2.847 | 3.658 | 3.64 | 2.894 | 1.685 |
Niet-Geldelijke Posten | 23.026 | -19.44 | -8.313 | 1.539 | -1.188 |
Cash Taxes Paid | 0.448 | 0.381 | 0.139 | 0.013 | 0.348 |
Veranderingen in het Operationeel Kapitaal | 4.677 | 59.176 | 4.295 | 0.281 | 1.588 |
Geldmiddelen uit Investeringsactiviteiten | -16.812 | -381.721 | -53.855 | 11.194 | 2.049 |
Kapitaaluitgaven | -7.167 | -2.538 | -1.836 | -5.259 | -3.7 |
Overige Cash Flow investeringsposten, Totaal | -9.645 | -379.183 | -52.019 | 16.453 | 5.749 |
Geldmiddelen uit Financieringsactiviteiten | 7.952 | 541.274 | 28.684 | 80.273 | 1.129 |
Uitgifte (Aflossing) van aandelen, netto | 7.927 | 541.274 | 30.442 | 80.273 | 1.129 |
Nettowijziging in Geldmiddelen | -79.529 | 176.31 | -51.23 | 67.756 | -12.129 |
Financiering van Cash Flow Posten | 0.025 | 0 | -1.758 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -34.451 | -101.219 | -70.504 | -35.493 | -0.523 |
Cash From Operating Activities | -39.722 | -70.669 | -50.931 | -40.293 | -10.921 |
Cash From Operating Activities | 0.969 | 2.847 | 2.195 | 1.614 | 0.887 |
Non-Cash Items | 16.798 | 23.026 | 7.164 | -3.581 | -16.21 |
Cash Taxes Paid | 0.037 | 0.448 | 0.236 | 0.224 | 0.119 |
Changes in Working Capital | -23.038 | 4.677 | 10.214 | -2.833 | 4.925 |
Cash From Investing Activities | 36.304 | -16.812 | 5.279 | -47.097 | -61.909 |
Capital Expenditures | -1.696 | -7.167 | -6.21 | -3.427 | -0.513 |
Other Investing Cash Flow Items, Total | 38 | -9.645 | 11.489 | -43.67 | -61.396 |
Cash From Financing Activities | 0.908 | 7.952 | 6.735 | 5.293 | 3.656 |
Issuance (Retirement) of Stock, Net | 0.908 | 7.927 | 6.71 | 5.268 | 3.656 |
Net Change in Cash | -2.51 | -79.529 | -38.917 | -82.097 | -69.174 |
Financing Cash Flow Items | 0.025 | 0.025 | 0.025 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
Bill & Melinda Gates Foundation Trust | Endowment Fund | 11.2027 | 6981664 | 0 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.1958 | 5107748 | 63870 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 6.1809 | 3852037 | 87330 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5071 | 3432108 | 214844 | 2022-12-31 | LOW |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 4.158 | 2591296 | 349109 | 2022-12-31 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 4.0185 | 2504407 | 94630 | 2022-12-31 | LOW |
Schrodinger Equity Holdings LLC | Corporation | 3.847 | 2397513 | -7260829 | 2021-12-01 | |
Baillie Gifford & Co. | Investment Advisor | 2.9233 | 1821858 | 640051 | 2022-12-31 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 2.2808 | 1421435 | 1421435 | 2022-12-31 | HIGH |
Friesner (Richard A) | Individual Investor | 1.97 | 1227703 | 0 | 2022-04-19 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.8294 | 1140112 | 79505 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.618 | 1008367 | 24525 | 2022-12-31 | LOW |
Rubric Capital Management LP | Hedge Fund | 1.6046 | 1000000 | -77621 | 2022-12-31 | MED |
Stephens Investment Management Group, LLC | Investment Advisor | 1.2511 | 779715 | 3183 | 2022-12-31 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1777 | 733941 | 195764 | 2022-12-31 | LOW |
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH | Investment Advisor | 1.1686 | 728300 | 0 | 2023-01-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.1232 | 700000 | 0 | 2022-12-31 | LOW |
Tocqueville Asset Management LP | Investment Advisor/Hedge Fund | 1.0707 | 667285 | 296005 | 2022-12-31 | LOW |
Pertento Partners LLP | Investment Advisor | 1.0213 | 636507 | 32824 | 2022-12-31 | MED |
Baron Capital Management, Inc. | Investment Advisor/Hedge Fund | 0.9941 | 619545 | -88259 | 2022-12-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Schrödinger, Inc. Company profile
Over Schrödinger, Inc.
Schrodinger, Inc. heeft een op fysica gebaseerd softwareplatform ontwikkeld, dat de ontdekking van moleculen voor de ontwikkeling van geneesmiddelen en materiaaltoepassingen mogelijk maakt. Het softwareplatform wordt gebruikt door biofarmaceutische en industriële bedrijven, academische instellingen en overheidslaboratoria over de hele wereld. De Onderneming gebruikt haar softwareplatform ook om samenwerkingsprogramma's en haar eigen pijplijn van therapeutica te ontwikkelen om tegemoet te komen aan onbeantwoorde medische noden. De Vennootschap is actief in twee segmenten: software en geneesmiddelenonderzoek. Het softwaresegment is gericht op de verkoop van software om de ontdekking van geneesmiddelen te transformeren in de biowetenschappelijke industrie, maar ook aan klanten in de materiaalwetenschappelijke industrie. Het segment drug discovery is gericht op het opbouwen van een portefeuille van preklinische en klinische programma's, zowel intern als via samenwerkingsverbanden, die zich in verschillende stadia van ontdekking en ontwikkeling bevinden. De pijplijn met programma's voor geneesmiddelenonderzoek van de Vennootschap omvat MALT1, CDC7, Wee1, en SOS1/KRAS.
Industry: | Software (NEC) |
1540 Broadway
24Th Floor
NEW YORK
NEW YORK 10036
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen